Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion to $60 from $50 and keeps an Overweight rating on the shares. The late breaking American Diabetes Association poster for Biomea’s menin inhibitor showed improvement and maintenance of reduced HbA1c at week 12, increased C-peptide and improved oral glucose tolerance – suggesting improved beta cell function, the analyst tells investors in a research note. Overall, the potential of a non-chronic treatment in diabetes is encouraging, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
- Biomea Soars on Promising Phase 2 Data in Type 2 Diabetes
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- Citi ups Biomea Fusion target to $90, elevates to ‘Top Pick’
- Biomea Fusion presents data from initial cohorts of Phase II study of BMF-219